Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 571 participants.

Also called NCT02526524

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 571 participants (enrolled count) (from the registry)
Sponsor
Elcelyx Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT02526524
Other papers using this trial's data
  • Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes PloS one, 2018 DOI, PubMed 30252913, PMC6155522 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02526524. Randomized; quadruple masking; primary purpose treatment. Start 2015-09 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2018-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Met DR
Intervention (Drug)
Met IR
Intervention (Drug)
Placebo
Lead sponsor
Elcelyx Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02526524
Content hash
adf5b80b231db322fa72a17bf5756dafac9b8ce1ee2444eb3c4c6b8fa42e73c1